Sinclair, Inc. (SBGI)
NASDAQ: SBGI · Real-Time Price · USD
11.93
-0.43 (-3.52%)
At close: Aug 8, 2025, 4:00 PM
12.10
+0.17 (1.47%)
After-hours: Aug 8, 2025, 7:48 PM EDT
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 6 analysts that cover Blueprint Medicines stock have a consensus rating of "Buy" and an average price target of $19.75, which forecasts a 65.62% increase in the stock price over the next year. The lowest target is $13 and the highest is $29.
Price Target: $19.75 (+65.62%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Blueprint Medicines stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $17 → $16 | Hold | Maintains | $17 → $16 | +34.17% | Aug 7, 2025 |
| Benchmark | Benchmark | Strong Buy Maintains $29 → $27 | Strong Buy | Maintains | $29 → $27 | +126.42% | Aug 7, 2025 |
| JP Morgan | JP Morgan | Sell Maintains $14 → $13 | Sell | Maintains | $14 → $13 | +9.01% | May 21, 2025 |
| Benchmark | Benchmark | Strong Buy Maintains $30 → $29 | Strong Buy | Maintains | $30 → $29 | +143.19% | May 6, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $19 → $17 | Strong Buy | Maintains | $19 → $17 | +42.56% | Mar 10, 2025 |
Financial Forecast
Revenue This Year
3.26B
from 3.55B
Decreased by -8.00%
Revenue Next Year
3.58B
from 3.26B
Increased by 9.59%
EPS This Year
-3.78
from 4.69
EPS Next Year
2.08
from -3.78
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.4B | 3.8B | 3.7B | ||
| Avg | 3.3B | 3.6B | 3.3B | ||
| Low | 3.1B | 3.4B | 2.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.0% | 15.4% | 4.4% | ||
| Avg | -8.0% | 9.6% | -8.1% | ||
| Low | -12.8% | 3.3% | -22.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.48 | 5.10 | -0.41 | ||
| Avg | -3.78 | 2.08 | -0.93 | ||
| Low | -4.96 | 0.52 | -1.40 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.